Progress, paradox, and potential: Parathyroid hormone research over five decades

Annals of the New York Academy of Sciences

Volumn 1117, Issue , 2007, Pages 196-208

  Potts, John T ^a   Gardella, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Parathyroid hormone; PTH

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; PARATHYROID RELATED PROTEIN; PEPTIDE HORMONE; PLACEBO; PROTEIN; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; BONE DEVELOPMENT; BONE MASS; BONE MINERAL; CALCIUM DEFICIENCY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; HISTORY OF MEDICINE; HORMONAL THERAPY; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OSTEOPOROSIS; PROTEIN CONFORMATION; PROTEIN PURIFICATION; RADIOIMMUNOASSAY;

EID: 36549086789     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.088     Document Type: Conference Paper

References (39)

1. AURBACH, G.D. 1959. Isolation of parathyroid hormone after extraction with phenol. J. Biol. Chem. 234: 3179-3181.
2. POTTS, J.T. 2005. Parathyroid hormone: past and present. J. Endocrinol. (UK) 187: 311-325.
3. MUNSON, P.L. 1961. Biological assay of parathyroid hormone. In The Parathyroids. R.O. Greer, Ed.: 94-113. Charles C. Thomas, Springfield, IL.
4. BAUER, W., J.C AUB & F. ALBRIGHT. 1929. Studies of calcium phosphorus metabolism. V. A study of the bone trabeculae as a readily available reserve supply of calcium. J. Exper. Med. 49: 145-162.
5. COLLIP, J.B. 1925. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J. Biol. Chem. 63: 395-438.
6. HANSON, A.M. 1924. The hydrochloric X sicca: a parathyroid preparation for intramuscular injection. Military Surg. 259: 218-219.
7. RASMUSSEN, H. & L.C. CRAIG. 1959. Purification of parathyroid hormone by use of counter-current distribution. J. Amer. Chem. Soc. 81: 5003.
8. BREWER, H.B., JR. & R. RONAN. 1970. Bovine parathyroid hormone: amino acid sequence. PNAS 67: 1862-1869.
9. NIALL, H.J., H.T. KEUTMANN, M. HOGAN, et al. 1970. The amino acid sequence of bovine parathyroid hormone. I. Hoppe-Seyler's Z. Physiol. Chem. 351: 1586-1588.
10. BREWER, H.B., JR. & R. RONAN. 1970. Bovine parathyroid hormone: amino acid sequence. PNAS 67: 1862-1869.
11. NIALL, H.D., R.T. SAUER, J.W. JACOBS, et al. 1974. The amino acid sequence of the amino-terminal 37 residues of human parathyroid hormone. PNAS 71: 384-388.
12. KEUTMAN, H.T., M.M. SAUER, G.N. HENDY, et al. 1978. The complete amino acid sequence of human parathyroid hormone. Biochemistry 17: 5723-5729.
13. SAUER R.T., H.D. NIALL, M.L. HOGAN, et al. 1974. The amino acid sequence of porcine parathyroid hormone. Biochemistry 13: 1994-1999.
14. POTTS, J.T., JR., G.W. TREGEAR, H.T. KEUTMANN, et al. 1971. Synthesis of a biologically active N-terminal tetratriacontapeptide of parathyroid hormone. PNAS 68: 63-67.
15. TREGEAR, G.W., J. VAN RIETSCHOTEN, E. GREENE, et al. 1974. Solid-phase synthesis of the biologically active N-terminal 1-34 peptide of human parathyroid hormone. Hoppe-Seyler's Z. Physiol. Chem. 355: 415-421.
16. TREGEAR, G.W., J. VAN RIETSCHOTEN, E. GREENE, et al. 1973. Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology 93: 1349-1353.
17. REEVE, J., P.J. MEUNIER, J.A. PARSONS, et al. 1980. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br. Med. J. 280: 1340-1344.
18. JÜPPNER, H., T.J. GARDELLA, E.M. BROWN, et al. 2006. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone. In Endocrinology, 5th ed. L.L. DeGroot & J.L. Jameson, Eds.: 1377-1417. Elsevier & Saunders. Philadelphia, PA.
19. MARTIN, T.J., D.M. FINDLAY & P.M. SEXTON. 2006. Calcitonin. In Endocrinology, 5th ed. L.L. DeGroot & J.L. Jameson, Eds.: 1419-1433. Elsevier & Saunders. Philadelphia, PA.
20. JÜPPNER, H. & J.T. POTTS, JR. 2002. Immunoassays for the detection of parathyroid hormone. J. Bone Miner. Res. 17(Suppl 2): N81-N86.
21. POTTS, J.T., JR., Ed. 1991. Proceedings of the NIH consensus development conference on diagnosis and management of asymptomatic primary hyperparathyroidism. J. Bone Miner. Res. 6(Suppl 2): S1-S165.
22. BILEZIKIAN, J.P., J.T. POTTS, JR., G. EL-HAJJ FULEIHAN, et al. 2002. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J. Bone Miner. Res. 17(Suppl 2): N2-N12.
23. RODAN, G.A. & T.J. MARTIN. 200. Therapeutic approaches to bone diseases. Science 289: 1508-1514.
24. HARADA, S. & G.A. RODAN. 2003. Control of osteoblast function and regulation of bone mass. Nature 423: 349-355.
25. NEER, R.M., C.D. ARNAUD, J.R. ZANCHETTA, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausalwomen with osteoporosis. N. Engl. J. Med. 344: 1434-1441.
26. DELMAS, P.D. & R.D. CHAPURLAT. 2006. Osteoporosis. In Endocrinology, 5th ed. L.L. DeGroot & J.L. Jameson, Eds.: 1751-1769. Elsevier & Saunders. Philadelphia, PA.
27. HORWITZ, M.J., M.B. TEDESCO, S.M. SEREIKA, et al. 2005. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteopor. Int. 17: 225-230.
28. HORWITZ, M.J., M.B. TEDESCO, S.M. SEREIKA, et al. 2006. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J. Bone Miner. Res. 20: 1792-1803.
29. DELEAN, A., J. STADEL & R. LEFKOWITZ. 1980. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled b-adrenergic receptor. J. Biol. Chem. 255: 7108-7117.
30. KENAKIN, T. 2004. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 25: 186-192.
31. SHIMIZU, N., T. DEAN, J.C. TSANG, et al. 2005. Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor. J. Biol. Chem. 280: 1797-1807.
32. DEAN, T., A. LINGLART, M.J. MAHON, et al. 2006. Mechanisms of ligand binding to the PTH/PTHrP receptor: selectivity of a modified PTH(1-15) radioligand for Gαs-coupled receptor conformations. Mol. Endocrinol. 20: 931-943.
33. SHIMIZU, N., P. CARTER, A. KHATRI, et al. 2001. Enhanced activity in parathyroid hormone (1-14) and (1-11): novel peptides for probing the ligand-receptor interaction. Endocrinology 142: 3068-3074.
34. TAKASU, H., J. GUO, F.R. BRINGHURST. 1999. Dual signaling and ligand selectivity of the human PTH/PTHrP receptor. J. Bone Miner. Res. 14: 11-20.
35. IIDA-KLEIN, A., J. GUO, M. TAKEMURA, et al. 1997. Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity. J. Biol. Chem. 272: 6882-6889.
36. DEAN, T., J.-P. VILARDAGA, J.T. POTTS, JR., et al. 2007. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein for distinct conformations of the PTH/PTHrP receptor. Mol. Endocrinol. Epub Sept. 13.
37. NAGAI, S., M. OKAZAKI, J.T. POTTS, JR., et al. 2007. Dissection of the mechanisms of PTH-mediated inhibition of sodium-dependent phosphate transport using a long-acting PTH(1-28) analog. J. Bone Miner. Res. 22(Suppl 2): 1189. Abstract.
38. OKAZAKI, M., S. NAGAI, T. DEAN, et al. 2007. Analysis of PTH-PTH receptor interaction mechanisms using a new, long-acting PTH(1-28) analog reveals selective binding to distinct PTH receptor conformations and biological consequences in vivo. J. Bone Miner. Res. 22(Suppl 2): 1190. Abstract.
39. VILARDAGA, J.-P., M. BUNEMANN, C. KRASEL, et al. 2003. Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat. Biotechnol. 21: 807-812.